Current Duke Appointments & Affiliations
Assistant Professor of Medicine
·
2023 - Present
Medicine, Medical Oncology,
Medicine
Member of the Duke Cancer Institute
·
2024 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Scholarly Works
Phase 2 multicenter trial of chemoimmunotherapy for patients with neuroendocrine or aggressive variant metastatic prostate cancer (CHAMP).
Conference Journal of Clinical Oncology · June 1, 2026 5016Background: Platinum-doublet chemotherapy is effective in pts with neuroendocrine ... Full text CiteAssociation between the rs72725854(A>T) allele and prostate cancer in males of African ancestry in a US population-based database.
Conference Journal of Clinical Oncology · June 1, 2026 10504Background: Black males have a 70% excess incidence of and two-fold higher morta ... Full text CiteValidation of electronic phenotyping algorithms for prostate cancer in All of Us and their impact on genetic association studies.
Conference Journal of Clinical Oncology · June 1, 2026 1619Background: The All of Us Full text CiteRecent Grants
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer (KLK2-PASenger, 78278343PCR3003)
Clinical TrialPrincipal Investigator · Awarded by Janssen Research & Development, LLC · 2026 - 2030A Randomized, 2-cohort, Double-blind, Placebo-controlled, Phase III Study of AZD5305 in Combination with Physician's Choice New Hormonal Agents in Patients with HRRm and non-HRRm Metastatic Castration-Sensitive Prostate Cancer (EvoPAR-Prostate01)
Clinical TrialPrincipal Investigator · Awarded by AstraZeneca AB · 2024 - 2029TulmiSTAR-02: A two-part Phase I dose escalation study of tulmimetostat (DZR123) in combination with darolutamide or abiraterone followed by open-label, randomized, Phase II dose expansion study to assess the safety and efficacy of tulmimetostat in c
Clinical TrialPrincipal Investigator · Awarded by Novartis Pharmaceuticals Corporation · 2025 - 2029View All Grants
Education
Icahn School of Medicine at Mount Sinai ·
2017
M.D.